[HTML][HTML] Liposomes and Their Therapeutic Applications in Enhancing Psoriasis and Breast Cancer Treatments
AA Elkordy, D Hill, M Attia, CS Chaw - Nanomaterials, 2024 - pmc.ncbi.nlm.nih.gov
Psoriasis and breast cancer are two examples of diseases where associated inflammatory
pathways within the body's immune system are implicated. Psoriasis is a complex, chronic …
pathways within the body's immune system are implicated. Psoriasis is a complex, chronic …
Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations
S Esposito, L Orsatti, V Pucci - Xenobiotica, 2022 - Taylor & Francis
Many peptide drugs such as insulin and glucagon-like peptide (GLP-1) analogues are
successfully administered subcutaneously (SC). Following SC injection, peptides may …
successfully administered subcutaneously (SC). Following SC injection, peptides may …
Experimental validation of a parenteral permitted daily exposure value for cleaning-induced degradants from recombinant therapeutic proteins with in vitro …
JR Cohen, MK Joubert, S Tabassum, A Capili… - Journal of …, 2024 - Elsevier
Multiproduct manufacturing of biotherapeutic proteins generate cleaning-induced protein
degradants because of extreme pH and temperature conditions during the cleaning process …
degradants because of extreme pH and temperature conditions during the cleaning process …
Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients
SG Thacker, C Her, L Kelley-Baker… - Frontiers in …, 2022 - frontiersin.org
Unintended immunogenicity can affect the safety and efficacy of therapeutic proteins and
peptides, so accurate assessments of immunogenicity risk can aid in the selection …
peptides, so accurate assessments of immunogenicity risk can aid in the selection …
A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics
NL Jarvi, SV Balu-Iyer - Communications Medicine, 2023 - nature.com
Background The efficacy and safety of therapeutic proteins are undermined by
immunogenicity driven by anti-drug antibodies. Immunogenicity risk assessment is critically …
immunogenicity driven by anti-drug antibodies. Immunogenicity risk assessment is critically …
A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic
JR Cohen, SR Brych, S Prabhu, V Bi… - Pharmaceutical …, 2024 - Springer
Abstract Background and Purpose There is concern that subvisible aggregates in
biotherapeutic drug products pose a risk to patient safety. We investigated the threshold of …
biotherapeutic drug products pose a risk to patient safety. We investigated the threshold of …